Optimizing management of patients with visual impairments as a result of diabetic macular edema. Role and place of the anti-VEGF-preparation aflibercept
DOI:
https://doi.org/10.31288/oftalmolzh201634954Abstract
Optimizing management of patients with visual impairments as a result of diabetic macular edema. Role and place of the anti-VEGF-preparation aflibercept
References
1.American Academy of Ophthalmology Retina/Vitreous Panel (2014) Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology. Available at: http://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp--. Accessed February 7, 2015.
2.Bandello F., Cunha-Vaz J., Chong N.V. et al. (2012) New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond.), 26(4): 485-493. https://doi.org/10.1038/eye.2011.337
3.Brown D.M., Schmidt-Erfurth U., Do D.V. et al. (2015) Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology, 122(10): 2044-2052.https://doi.org/10.1016/j.ophtha.2015.06.017
4.Ciulla T.A., Amador A.G., Zinman B. (2003) Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care, 26(9): 2653-2664.https://doi.org/10.2337/diacare.26.9.2653
5.Coyne K.S., Margolis M.K., Kennedy-Martin T. et al. (2004) The impact of diabetic retinopathy: perspectives from patient focus groups. Fam. Pract., 21(4): 447-453.https://doi.org/10.1093/fampra/cmh417
6.Davidson J.A., Ciulla T.A., McGill J.B. et al. (2007) How the diabetic eye loses vision. Endocrine, 32(1): 107-116.https://doi.org/10.1007/s12020-007-0040-9
7.Diabetic Retinopathy Clinical Research Network, Wells J.A., Glassman A.R., Ayala A.R. et al. (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N. Engl. J. Med., 372(13): 1193-1203).https://doi.org/10.1056/NEJMoa1414264
8.Ding J., Wong T.Y. (2012) Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr. Diab. Rep., 12(4): 346-354.https://doi.org/10.1007/s11892-012-0283-6
9.Early Treatment Diabetic Retinopathy Study research group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch. Ophthalmol., 103(12): 1796-1806.https://doi.org/10.1001/archopht.1985.01050120030015
10.Early Treatment Diabetic Retinopathy Study Research Group (1991) Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology, 98(5 Suppl.): 766-785.https://doi.org/10.1016/S0161-6420(13)38011-7
11.Fauser S., Schwabecker V., Muether P.S. (2014) Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am. J. Ophthalmol., 158(3): 532-536.https://doi.org/10.1016/j.ajo.2014.05.025
12.Ford J.A., Lois N., Royale P. et al. (2013) Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open, 3(3): e002269.https://doi.org/10.1136/bmjopen-2012-002269
13.Grover D., Li T.J., Chong C.C. (2008) Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev., 1: CD005656.https://doi.org/10.1002/14651858.CD005656.pub2
14.International Council of Ophthalmology (2014) ICO Guidelines for Diabetic Eye Care. Available at: http://www.icoph.org/enhancing_eyecare/international_clinical_guidelines. Accessed February 7, 2015.
15.International Diabetes Federation - IDF (2015) IDF Diabetes Atlas, 7 ed. Brussels, Belgium, 144 р.
16.Korobelnik J.F., Do D.V., Schmidt-Erfurth U. et al. (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology, 121(11): 2247-2254.https://doi.org/10.1016/j.ophtha.2014.05.006
17.Luckie R., Leese G., McAlpine R. et al.; DARTS/MEMO Collaboration (2007) Fear of visual loss in patients with diabetes: results of the prevalence of diabetic eye disease in Tayside, Scotland (P-DETS) study. Diabet. Med., 24(10): 1086-1092.https://doi.org/10.1111/j.1464-5491.2007.02180.x
18.Mitchell P., Wong T.Y.; Diabetic Macular Edema Treatment Guideline Working Group (2014) Management paradigms for diabetic macular edema. Am. J. Ophthalmol., 157(3): 505-513.https://doi.org/10.1016/j.ajo.2013.11.012
19.Muether P.S., Hermann M.M., Dr?ge K. et al. (2013) Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am. J. Ophthalmol., 156(5): 989-993.https://doi.org/10.1016/j.ajo.2013.06.020
20.Papadopoulos N., Martin J., Ruan Q. et al. (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis, 15(2): 171-185.https://doi.org/10.1007/s10456-011-9249-6
21.The Royal College of Ophthalmologists (2012) Diabetic Retinopathy Guidelines. Available at: https://www.rcophth.ac.uk/standards-publications-research/clinical-guide. Accessed February 7, 2015.
22.Yau J.W., Rogers S.L., Kawasaki R. et al.; Meta-Analysis for Eye Disease (META-EYE) Study Group (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 35(3): 556-564.https://doi.org/10.2337/dc11-1909
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Віталій Фуголь
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
